Pathstone Family Office’s West Pharmaceutical WST Stock Holding History

Pathstone Family Office’s Portfolio WST Stock Details WST Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	$1.7M	Buy	4,521 +491	+12%	+$190K	0.01%	505
2023 Q2	$1.56M	Buy	4,030 +231	+6%	+$82.5K	0.02%	366
2023 Q1	$1.32M	Sell	3,799 -13,761	-78%	-$4.02M	0.02%	374
2022 Q4	$2.97M	Buy	17,560 +10,508	+149%	+$2.49M	0.03%	394
2022 Q3	$1.73M	Buy	7,052 +3,975	+129%	+$1.21M	0.02%	492
2022 Q2	$931K	Sell	3,077 -1,897	-38%	-$617K	0.02%	361
2022 Q1	$2.04M	Sell	4,974 -312	-6%	-$122K	0.05%	172
2021 Q4	$2.48M	Buy	5,286 +542	+11%	+$233K	0.06%	156
2021 Q3	$2.01M	Buy	4,744 +292	+7%	+$123K	0.06%	168
2021 Q2	$1.6M	Buy	4,452 +3,119	+234%	+$1.03M	0.05%	181
2021 Q1	$376K	Buy	+1,333	New	+$382K	0.01%	415

Other funds holding WST

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

APG Asset Management Amsterdam, Netherlands $31.6B AUM 19.33% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return

Pathstone Family Office's WST Position: Q3 2023 in Review

Pathstone Family Office increased its West Pharmaceutical (WST) stake by 12% in Q3 2023, buying an estimated $190K and bringing the position to 4,521 shares worth $1.7M. The position accounts for 0.01% of the portfolio, ranked #505.

Pathstone Family Office first reported a position in WST in Q1 2021 and has held it in 11 quarters since. The position peaked at $2.97M in Q4 2022. 758 funds tracked by Wall St. Rank hold WST as of Q3 2023.

Pathstone Family Office held 4,521 shares of West Pharmaceutical worth $1.7M as of Q3 2023.
Pathstone Family Office bought 491 West Pharmaceutical shares in Q3 2023, an estimated $190K.
West Pharmaceutical made up 0.01% of Pathstone Family Office's portfolio in Q3 2023, its #505 holding.
Pathstone Family Office first reported a position in West Pharmaceutical in Q1 2021 and has held it in 11 quarters since.
Pathstone Family Office's West Pharmaceutical position peaked at $2.97M in Q4 2022.
758 funds tracked by Wall St. Rank held West Pharmaceutical as of Q3 2023.

Based on Pathstone Family Office's 13F filing for Q3 2023, filed 8 Nov 2023.